Out of stock
Safety Advices
বাংলা
English
CONSULT YOUR DOCTOR
It is not known whether it is safe to consume alcohol with Vincristine PCH. Please consult your doctor.
CONSULT YOUR DOCTOR
Vincristine PCH is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
UNSAFE
Vincristine PCH is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.
UNSAFE
Vincristine PCH may cause side effects which could affect your ability to drive.
CAUTION
Vincristine PCH should be used with caution in patients with kidney disease. Dose adjustment of Vincristine PCH may be needed. Please consult your doctor.
CAUTION
Vincristine PCH should be used with caution in patients with liver disease. Dose adjustment of Vincristine PCH may be needed. Please consult your doctor.
Medicine Overview of Vincristine PCH 1mg/ml Injection
Introduction
Vincristine PCH is an anti-cancer medication used in the treatment of breast cancer, non-small cell lung cancer, pancreatic cancer, kidney cancer, blood cancer, multiple myeloma, lymphomas and bone cancer. Vincristine PCH is given as an injection into the vein under the supervision of a doctor. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause...
... Show moreUses of Vincristine PCH
- Breast cancer
- Non-small cell lung cancer
- Pancreatic cancer
- Kidney cancer
- Blood cancer
- Multiple myeloma
- Lymphomas
- Bone cancer
Side effects of Vincristine PCH
Common
- Hair loss
- Peripheral neuropathy (tingling and numbness of feet and hand)
- Constipation
How to use Vincristine PCH
Your doctor or nurse will give you this medicine. Kindly do not self administer.
How Vincristine PCH works
Vincristine PCH blocks replication of genetic material (DNA) in the cancer cells. Thus it stops the growth and multiplication of cancer cells.
Quick Tips
- Avoid being near people suffering from infections (such as, cold, flu, contagious illnesses), as you may be more susceptible to infections, while on vincristine therapy, because of possibility of leukopenia.
- Avoid even accidental contamination of eyes with vincristine as it may cause severe irritation.
- Vincristine may cause acute kidney disease (nephropathy) related to uric acid level.
- Care should be taken in elderly patients because they are more susceptible to neurotoxic effects of vincristine.
- In males, vincristine may cause aspermia (lack of semen causing infertility); in females vincristine may cause amenorrhea (absence of menstruation), which may recover after some duration.
- Tell your doctor if you are or planning to become pregnant or are breastfeeding.
Brief Description
Indication
Acute lymphoblastic leukaemia, Acute myeloid leukaemia, AIDS-related Kaposi's sarcoma, Brain tumours, Hodgkin's disease, Neuroblastoma, Non-Hodgkin's lymphoma, Small cell lung cancer, Wilm's tumour
Adult Dose
Intravenous
Acute lymphoblastic leukaemia
Adult: Usual recommended dosage: 1.4-1.5 mg/m2 once wkly. Max: 2 mg wkly. Subsequent doses may be modified based on clinical and haematological responses and tolerance of the patient.
May be used in combination with other drugs. Prescribers should consult published protocols for the dosage, method and sequence of admin.
Hepatic impairment: Dose adjustment may be needed. Serum bilirubin >3 mg/100ml: Reduce dose by 50%.
Child Dose
Intravenous
Acute lymphoblastic leukaemia
Child: Usual recommended dosage: 1.5-2 mg/m2 once wkly; for patients ?10 kg: Initiate at 0.05 mg/kg once wkly. Subsequent doses may be modified based on clinical and haematological responses and tolerance of the patient.
May be used in combination with other drugs. Prescribers should consult published protocols for the dosage, method and sequence of admin.
Renal Dose
Renal Impairment
Dose adjustment not necessary
Contraindication
Patients with demyelinating form of Charcot-Marie-Tooth syndrome. Pregnancy and lactation. Intrathecal admin (may be fatal). Patients receiving radiation therapy through ports which include liver.
Mode of Action
Vincristine arrests cell division at the metaphase stage by inhibiting microtubule formation in the mitotic spindle.
Precaution
Elderly. Preexisting pulmonary dysfunction or neuromuscular disease; leucopenia or a complicating infection; impaired liver function; obstructive jaundice. Routine prophylactic laxative needed to ensure regular bowel movement. Discontinue immediately if extravasation occurs, and inj any remaining drug into another vein, followed by local Inj of hyaluronidase and topical heat application to the affected area to aid in drug removal and reduce discomfort. Discontinue in patients who develop progressive dyspnea. CBC to be checked before each dose admin. Frequent monitoring of uric acid during first 3-4 wk of treatment and watch out for uric acid nephropathy. Lactation: not known if excreted in...
... Show moreSide Effect
>10%
Alopecia (20-70%)
Frequency Not Defined
Dose limiting neurotoxicity (e.g. motor function impairment, gait abnormalities), hyperuricaemia, bronchospasm, azospermia, amenorrhoea, alopoecia, leucopenia, urinary dysfunction, abdominal cramps, vomiting, diarrhoea, severe constipation, paralytic ileus, convulsions, hypertension, orthostatic hypotension, ptosis, hoarseness, optic neuropathies, hallucinations, blindness, neurological deafness, difficulty in walking, syndrome of inappropriate ADH secretion.
Potentially Fatal: Myelosuppression.
Interaction
Decreased digoxin (tablets) and verapamil absorption with antineoplastic regimens. Increased etoposide serum levels with vincristine. Increased toxicity when ganciclovir given with, immediately before or after vincristine. Reduced vincristine metabolism with miconazole. Increased neurotoxicity with isoniazid, itraconazole, voriconazole, posaconazole and nifedipine. Decreased immune response when used concurrently with vaccines. Increased myelotoxicity with zidovudine. Increased risk of thromboembolic complications with tamoxifen. Increased risk of ototoxicity with ototoxic drugs (e.g. platinum-containing antineoplastic agents). Possible risk of earlier onset and/or increased severity of adverse effects with macrolides. Possible increase in vincristine levels with aprepitant. Possible decrease in antiepileptic levels with vincristine, monitor serum antiepileptic...
... Show more